CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 434 · Search date 2026-07-17 · Methodology v0.6

Spermidine,
does it really help with Reduction of telogen hair loss and prolongation of anagen?

30-Second Summary
C
Evidence Grade C · 44 · Safety caution
A follicular surrogate signal does not establish treatment of telogen effluvium or actual hair regrowth
What the
research shows
A human trial reported a higher proportion of anagen follicles with a spermidine-based supplement, but it was a single manufacturer-funded study in 100 healthy adults and focused on surrogate measures such as stages of plucked follicles and the hair-pull test. No independent RCT establishing clinical shedding or hair-density improvement in patients with telogen effluvium was identified, so the grade is C.
What the
ads claim
Claims such as 'activates autophagy for hair growth,' 'blocks telogen shedding,' and 'extends anagen' convert follicle-culture mechanisms and limited surrogate evidence into actual hair regrowth. Longevity or cognition research is not evidence for hair efficacy.
*

Useful facts when choosing a product

  • Products sold online or imported into South Korea use wheat-germ-derived or high-purity spermidine and vary in labeled dose.
  • The key hair RCT used one tablet daily, but the actual spermidine dose and full composition were not clearly reported in the paper.
  • A combination supplement or wheat-germ product is not interchangeable with isolated spermidine.
Gap Measurement · Verdict 434 · C 44
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Rinaldi 2017 assigned 100 healthy adults to a supplement or placebo for 90 days and assessed anagen stages in 100 plucked follicles, Ki-67, c-Kit, and the hair-pull test. Some outcomes improved, but Giuliani fully funded the study and authors included employees and a consultant. Ramot 2011 and Parodi 2018 studied growth and autophagy in ex vivo human scalp follicles; neither was a clinical trial of oral spermidine alone for hair loss.

02

Why this is classified as C (44)

A randomized human trial exists, but the healthy population, surrogate outcomes, and single manufacturer-linked product limit the grade to C with 44 points.

Counterpoint. The anagen-follicle signal justifies independent follow-up trials but does not confirm clinical improvement of hair loss.

Rejudgment record. New verdict — A human RCT exists, but healthy-participant surrogate outcomes, one manufacturer-linked product, and no clinical hair-loss endpoint limit it to C

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prolongation of the anagen phaseCThe signal comes from the proportion of plucked anagen follicles in one RCT of healthy adults.
Reduction of telogen hair lossCA hair-pull signal exists, but there is no hair-count or density RCT in diagnosed telogen effluvium.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Rinaldi F et al. 2017Randomized, double-blind, placebo-controlled, single-center trial100Fully funded by Giuliani; employee and consultant authorsAnagen stage of plucked follicles, Ki-67, c-Kit, and hair-pull testThe proportion of anagen follicles and some markers improved after 90 days; there was no clinical hair-count or density endpoint.Key
Ramot Y et al. 2011Ex vivo human scalp-hair-follicle studyPartly funded by Giuliani with disclosed conflictsHair-shaft growth, anagen, and epithelial stem-cell markersLow concentrations of spermidine produced a follicle-growth signal; this was not an oral human trial.Mechanistic
Parodi C et al. 2018Human scalp-hair-follicle organ-culture mechanistic studyProduct-related collaborationAutophagy activity and maintenance of anagenAutophagy was involved in maintaining follicle growth, but clinical hair-growth efficacy was not tested.Mechanistic
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Rinaldi F, Marzani B, Pinto D, Ramot Y. A spermidine-based nutritional supplement prolongs the anagen phase of hair follicles in humans: a randomized, placebo-controlled, double-blind study. Dermatol Pract Concept. 2017;7(4):17-21. PMID: 29214104. DOI: 10.5826/dpc.0704a05.
checked
Ramot Y, Tiede S, Bíró T, et al. Spermidine promotes human hair growth and is a novel modulator of human epithelial stem cell functions. PLoS One. 2011;6(7):e22564. PMID: 21818338. DOI: 10.1371/journal.pone.0022564.
checked
Parodi C, Hardman JA, Allavena G, et al. Autophagy is essential for maintaining the growth of a human (mini-)organ: Evidence from scalp hair follicle organ culture. PLoS Biol. 2018;16(3):e2002864. PMID: 29590104. DOI: 10.1371/journal.pbio.2002864.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Spermidine x reduction of telogen hair loss and prolongation of anagen Evidence Grade C card
[Chamgap] Spermidine x reduction of telogen hair loss and prolongation of anagen — Evidence Grade C·44. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/skin-hair/spermidine-hair-growth-anagen/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.